Teva Pharmaceutical

TEVA-N

NYSE:TEVA

10.10
0.29 (2.79%)
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel.
More at Wikipedia

Analysis and Opinions about TEVA-N

Signal
Opinion
Expert
HOLD
HOLD
November 28, 2019
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
Show full opinionHide full opinion
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
DON'T BUY
DON'T BUY
August 15, 2019
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
Show full opinionHide full opinion
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
DON'T BUY
DON'T BUY
July 17, 2019
He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.
Show full opinionHide full opinion
He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.
DON'T BUY
DON'T BUY
July 3, 2019
A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.
Show full opinionHide full opinion
A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.
DON'T BUY
DON'T BUY
July 2, 2019
It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.
Show full opinionHide full opinion
It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.
DON'T BUY
DON'T BUY
May 22, 2019
He is more content owning the major pharma versus generic producers. The competition in the space too intense. They have been involved in the manufacturing of opiod based drugs, which could come under regulatory pressure.
Show full opinionHide full opinion
He is more content owning the major pharma versus generic producers. The competition in the space too intense. They have been involved in the manufacturing of opiod based drugs, which could come under regulatory pressure.
COMMENT
COMMENT
May 3, 2019
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
Show full opinionHide full opinion
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
BUY
BUY
March 11, 2019
He'd buy it here. It won't go much lower than current levels based on the chart.
Show full opinionHide full opinion
He'd buy it here. It won't go much lower than current levels based on the chart.
DON'T BUY
DON'T BUY
February 13, 2019
They do generic drugs, the largest player in the world. They're smart and great at what they do. But they made a big acqusition that pressured their margins and hurt the company. But management has since changed and the company is recovering. They're still reducing their debt. TEVA should continue to grow. But this turnaround will take time.
Show full opinionHide full opinion
They do generic drugs, the largest player in the world. They're smart and great at what they do. But they made a big acqusition that pressured their margins and hurt the company. But management has since changed and the company is recovering. They're still reducing their debt. TEVA should continue to grow. But this turnaround will take time.
BUY
BUY
December 7, 2018
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
Show full opinionHide full opinion
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
SELL
SELL
December 6, 2018
A great company. Generics are fantastic. There are internal issues. A lot of people are getting lured here by single digit earnings growth. The fundamental picture is not strong here. He would take the loss. He would look at an ETF if you want to stay invested in Pharma. (Analysts’ price target is $23.00)
Show full opinionHide full opinion
A great company. Generics are fantastic. There are internal issues. A lot of people are getting lured here by single digit earnings growth. The fundamental picture is not strong here. He would take the loss. He would look at an ETF if you want to stay invested in Pharma. (Analysts’ price target is $23.00)
DON'T BUY
DON'T BUY
November 12, 2018
It is a big generics play. It has been run fairly well over the years. They are reducing debt. It is okay. There is going to be a lot of selling pressure at the $30 level. Quarterly numbers are okay but there is so much out there that is better. He would use a health device and equipment ETF (IHI-N).
Show full opinionHide full opinion
It is a big generics play. It has been run fairly well over the years. They are reducing debt. It is okay. There is going to be a lot of selling pressure at the $30 level. Quarterly numbers are okay but there is so much out there that is better. He would use a health device and equipment ETF (IHI-N).
COMMENT
COMMENT
October 1, 2018

Generic drugs. Teva will benefit from an aging population and a growing push by governments to make drugs cheaper. However, Teva has been facing competition from other generic makers. In the long term, though, this will be a winner in this space.

Show full opinionHide full opinion

Generic drugs. Teva will benefit from an aging population and a growing push by governments to make drugs cheaper. However, Teva has been facing competition from other generic makers. In the long term, though, this will be a winner in this space.

WATCH
WATCH
September 5, 2018

A leader in generic pharmaceuticals. It's sold off the past few years and he hasn't look at it recently. Hold on. It's bottoming. Look at its fundamentals. This is the right sector, but do your homework on it.

Show full opinionHide full opinion

A leader in generic pharmaceuticals. It's sold off the past few years and he hasn't look at it recently. Hold on. It's bottoming. Look at its fundamentals. This is the right sector, but do your homework on it.

Alex Ruus

Unlock Ratings

Price
$22.640
Owned
Unknown
DON'T BUY
DON'T BUY
August 20, 2018

He used to own it in the mid-2000's when they were positioned to benefit from new drugs coming off patent. This ended around 2011. Today, they have a lot of debt, and face declining drug prices.

Show full opinionHide full opinion

He used to own it in the mid-2000's when they were positioned to benefit from new drugs coming off patent. This ended around 2011. Today, they have a lot of debt, and face declining drug prices.

Showing 1 to 15 of 264 entries